Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Clinical trial NCT01641809 · COMPLETED
Trial details
- NCT number
- NCT01641809
- Sponsor
- ViiV Healthcare
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-08-06
- Primary completion
- 2013-10-10
- Enrollment
- 244
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.